Scarica l'app Stockscreener
2.43
14.08%
0.30
Dopo l'orario di chiusura:
2.49
0.06
+2.47%
Precedente Chiudi:
$2.13
Aprire:
$2.03
Volume 24 ore:
3.14M
Relative Volume:
3.40
Capitalizzazione di mercato:
$81.57M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.6075
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
+32.07%
1M Prestazione:
+4.74%
6M Prestazione:
+29.95%
1 anno Prestazione:
-66.89%
Intervallo 1D:
$1.945
$2.46
Intervallo di 1 settimana:
$1.81
$2.46
Portata 52W:
$0.87
$8.32
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.43 | 91.28M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics Q3 FY2025 Financial Results and Corporate Update - TradingView
Outlook Therapeutics at a Strategic Inflection Point: Regulatory and Commercial Catalysts for Value Creation in the $4B+ Anti-VEGF Market - AInvest
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook's Eye Drug LYTENAVA Launches in Europe as Critical FDA Decision Approaches - Stock Titan
Reversal Traders Monitor Outlook Therapeutics Inc. for EntryChart Breakout Buy Signal Detection Confirmed - 선데이타임즈
Outlook Therapeutics, Inc. shares rise 1.94% after-hours due to positive market sentiment. - AInvest
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024OTLK - ACCESS Newswire
Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 15:25:16 - metal.it
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News
What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News
What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News
What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News
How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News
When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News
Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News
How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News
How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News
Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest
What institutions are buying Outlook Therapeutics Inc. stock nowEntry Points For Growing Stocks Identified by Models - metal.it
Ichimoku Cloud Indicates Uncertainty Around Outlook Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
How many analysts rate Outlook Therapeutics Inc. as a “Buy”Build your wealth with consistent stock growth - Jammu Links News
Outlook Therapeutics Inc. stock outlook for YEAR Pattern Recognition Based Market Move Prediction - Newser
Why is Outlook Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with professional market insights - Jammu Links News
Published on: 2025-07-28 00:00:40 - Jammu Links News
Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser
Outlook Therapeutics Inc. Stock Support and Resistance Levels You Should KnowBig Return Stock Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
Outlook Therapeutics, Inc. shares fall 2.45% after-hours amid mixed market sentiment. - AInvest
What analysts say about Outlook Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia
Outlook Therapeutics to Present at OIS Retina Innovation Summit - AInvest
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):